# EDGAR Filing Document

**Accession Number:** 0001776111
**File Stem:** 0000000000-25-008532
**Filing Date:** 2025-8
**Character Count:** 2375
**Document Hash:** 8cdf48383d5f54eb0fdfc07cbaeca4c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008532.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0000000000-25-008532

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250813

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MBX Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001776111
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08307

**BUSINESS ADDRESS:**
- **STREET 1:** 11711 N. MERIDIAN STREET
- **STREET 2:** SUITE 300
- **CITY:** CARMEL
- **STATE:** IN
- **ZIP:** 46032
- **BUSINESS PHONE:** 3179893100

**MAIL ADDRESS:**
- **STREET 1:** 11711 N. MERIDIAN STREET
- **STREET 2:** SUITE 300
- **CITY:** CARMEL
- **STATE:** IN
- **ZIP:** 46032
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950123-25-007329

## Text-Extract

```

                                                            August 13, 2025

P. Kent Hawryluk
Chief Executive Officer
MBX Biosciences, Inc.
11711 N. Meridian Street, Suite 300
Carmel, IN 46032

       Re: MBX Biosciences, Inc.
           Draft Registration Statement on Form S-1
           Submitted August 8, 2025
           CIK No. 0001776111
Dear P. Kent Hawryluk:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Edwin O   Connor, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._